This article is more than 5 years old. Information may no longer be current.

FDA issues warning letter to DNA EGF Renewal

The FDA has sent a warning letter to DNA EFG Renewal for its product, DNA Eye Renewal, based on website claims that render the product as a drug.

The company’s website claims the product controls inflammation, stimulates collagen and stimulates the growth of new cells, which classifies the product as a drug under section 201(g)(1)(C) of the Federal Food, Drug and Cosmetic Act. As such, the product may not be legally introduced or delivered for interstate commerce without prior approval from the FDA.

The company has 15 days to respond with its course of action to correct the violations and ensure they do not reoccur, according to the FDA letter.

Reference: www.fda.gov.